Shares of Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $80.70 and last traded at $80.24, with a volume of 7026374 shares changing hands. The stock had previously closed at $73.88.
Analyst Upgrades and Downgrades
A number of equities analysts have recently commented on TEM shares. Stifel Nicolaus downgraded Tempus AI from a "buy" rating to a "hold" rating and raised their price objective for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Piper Sandler restated a "neutral" rating and issued a $70.00 price target (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Guggenheim started coverage on shares of Tempus AI in a research note on Monday, December 9th. They set a "buy" rating and a $74.00 price objective for the company. TD Cowen reissued a "buy" rating and issued a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Finally, Loop Capital decreased their price target on shares of Tempus AI from $57.00 to $52.00 and set a "buy" rating for the company in a research report on Tuesday, January 14th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $58.55.
Read Our Latest Analysis on TEM
Tempus AI Stock Performance
The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The stock has a 50-day moving average price of $46.60 and a 200-day moving average price of $50.32.
Insider Buying and Selling at Tempus AI
In other Tempus AI news, major shareholder Bradley A. Keywell sold 395,800 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the sale, the insider now directly owns 16,164,449 shares of the company's stock, valued at approximately $694,263,084.55. This represents a 2.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David R. Epstein sold 620 shares of Tempus AI stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total transaction of $25,922.20. Following the completion of the transaction, the director now directly owns 27,894 shares of the company's stock, valued at $1,166,248.14. This trade represents a 2.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,401,779 shares of company stock worth $115,707,361 in the last 90 days.
Hedge Funds Weigh In On Tempus AI
A number of large investors have recently bought and sold shares of TEM. Operose Advisors LLC acquired a new stake in shares of Tempus AI during the 4th quarter worth approximately $25,000. First Horizon Advisors Inc. bought a new position in Tempus AI during the 3rd quarter worth $30,000. Farther Finance Advisors LLC acquired a new stake in Tempus AI in the fourth quarter worth $34,000. Prestige Wealth Management Group LLC increased its position in Tempus AI by 910.4% in the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock worth $36,000 after buying an additional 965 shares during the period. Finally, NewEdge Advisors LLC bought a new stake in Tempus AI in the fourth quarter valued at $49,000. Institutional investors own 24.22% of the company's stock.
About Tempus AI
(
Get Free Report)
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Further Reading
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
